ISK LTD

Immune System Key (ISK) Ltd. is a biotechnology company focused on developing novel treatments for malignant and autoimmune diseases. Its proprietary lead compound, Nerofe, is a human secreted peptide engineered to provide a triple-action mechanism: inhibiting angiogenesis, stimulating the body's immune response, and directly suppressing cancer cell proliferation. The company’s technology is designed to target tumors expressing the ST2 receptor, effectively turning cold tumors into hot tumors to improve therapeutic efficacy in aggressive malignancies.

The company is currently advancing multiple clinical programs targeting high-risk patient populations with limited therapeutic options, including Acute Myeloid Leukemia (AML) and KRAS-mutated solid tumors. ISK has secured orphan drug status for Nerofe in AML and operates as a resident company within the Johnson & Johnson Innovation JLABS ecosystem. Its clinical development strategy involves ongoing trials in the United States, including studies at Georgetown University, to evaluate the safety and clinical activity of its compounds, both as single agents and in combination therapies.